Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=funder" }, "data": [ { "type": "Grant", "id": "12100", "attributes": { "award_id": "1T32AI177324-01", "title": "Immunology Research Training Grant", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6125, "first_name": "Timothy A.", "last_name": "Gondre-Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2028-08-31", "award_amount": 185410, "principal_investigator": { "id": 27961, "first_name": "Eric", "last_name": "Pearlman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 971, "ror": "", "name": "UNIVERSITY OF CALIFORNIA-IRVINE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Support is requested for four positions in a new training grant to continue and expand our successful Immunology Training Program at the University of California, Irvine (UCI). We have a total of 36 mentors that include junior, mid-level and senior training faculty comprising 14 women and 3 URM faculty. UCI immunology researchers are working on: a) host defense and vaccine development; b) tumor immunology and immunotherapy; c) Neurogenerative disease and microglia biology; d) chronic diseases and autoimmunity; and d) synthetic immunology. The pool of immunology graduate students comes primarily from the Cellular and Molecular Bology (CMB) intake program. In 2022, 101 students were accepted to CMB, including 39 URM (38.6%), and their mean GPA was 3.86 (which was similar to 2020 and 2021). There is substantial institutional support from the Office of Research and from the Graduate Division at UCI, which will provide full stipend and tuition for a 5th student. Our prior T32 from 2016-2021 supported 15 students, most of whom have graduated and are in research positions in industry or academia. Dr. Eric Pearlman is the Director of the UCI Institute for Immunology and was the Prinicipal Investigator of the previous T32 training grant. In the current submission, Dr. Pearlman will be PI/Director, and a new faculty recruit, Dr. Ivan Marazzi, will be co-Director. Dr. Pearlman has extensive experience in training graduate students and running T32 grants, and Dr. Marazzi has a very exciting and well funded research program in autoimmunity chronic neurodegenerative diseases and in molecular virology, including influenza and COVID-19. Given the outsanding training record of faculty and the quality of training grant elibile and URM students in the program, we fully anticipate that the UCI Immunology training program will continue to provide outstanding educational and career opportunities for the next generation of immunology researchers.", "keywords": [ "Grant", "Immunology", "Research Training" ], "approved": true } }, { "type": "Grant", "id": "12101", "attributes": { "award_id": "1R03HS029194-01A1", "title": "Telemedicine Preparation for Older Adults with Type 2 Diabetes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 27962, "first_name": "Matthew", "last_name": "Simpson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2024-08-31", "award_amount": 99174, "principal_investigator": { "id": 27963, "first_name": "GOUTHAM", "last_name": "RAO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27964, "first_name": "Kelsey", "last_name": "Ufholz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1952, "ror": "https://ror.org/0130jk839", "name": "University Hospitals of Cleveland", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "During the COVID-19 pandemic, many primary care appointments were converted to telemedicine. Telemedicine appointments may be especially beneficial for patients who are at high risk for COVID mortality, such as older adults, African Americans, and patients with type 2 diabetes. Numerous studies have found telemedicine can be an effective venue for diabetes care. Unfortunately, such interventions often assume that patients already have internet-capable devices, reliable internet service, and basic digital skills. Many patients, especially older patients and African Americans, lack the digital skills needed for telemedicine. Unfortunately, the net result is that those at highest risk for chronic diseases and their complications are often least able to take advantage of telemedicine. We propose a digital skills training intervention comprising essential basic skills to participate in a telemedicine appointment for older (age 50-70 years) mostly African American primary care patients with type 2 diabetes who already own an internet-capable device but have never had a telemedicine appointment. The intervention's goal is to prepare patients to have a successful telemedicine appointment. Patients will first be assessed for skills and then receive customized digital skills training through a community-based organization. Participants will also be scheduled to have a virtual diabetes management appointment within 6 months. For Specific Aim # 1, we will measure whether or not patients referred to the telemedicine training intervention complete a telemedicine appointment within 6 months. In Specific Aim # 2, we will interview patients and analyze interview transcripts to assess their experience with telemedicine. Patients who successfully completed a telemedicine appointment will be asked about their satisfaction with both the telemedicine training intervention and their telemedicine appointment. Patients who enrolled in the telemedicine training intervention but either did not complete a telemedicine appointment and/or did not complete telemedicine training will be asked about their barriers and how the telemedicine training intervention could better meet their needs.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12102", "attributes": { "award_id": "1R01DC021826-01", "title": "Odorprint Based Disease Diagnostics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6520, "first_name": "SUSAN L.", "last_name": "SULLIVAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2028-05-31", "award_amount": 931815, "principal_investigator": { "id": 27965, "first_name": "Dmitry", "last_name": "Rinberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2064, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "It has long been observed that certain diseases may be diagnosed by smell alone. There is mounting evidence supporting these observations, showing that the metabolic changes brought about by disease, expressed in biospecimens such as sweat, breath, urine and blood, can be accurately identified through olfaction. This is the case not only for metabolic diseases such as diabetes, but most notably cancer, Alzheimer’s, Parkinson’s, and many types of infection, including COVID-19. But it remains a mystery how olfactory systems achieve this ability, especially when faced with the stark levels of variance in healthy populations, and the challenge of identifying a complex odor object against irrelevant background components. This project will investigate the neural mechanisms of odor-based disease diagnostics in the olfactory system of the mouse. Initial experiments will image the responses of olfactory sensory neurons in the olfactory bulb of the awake mouse. Using mouse models of disease, we will collect urine samples corresponding to both disease and healthy states, with controlled between-sample variability. We will image glomeruli, with each glomerulus aggregating the axons of sensory neurons expressing the same class of receptor. Linear and nonlinear dimensionality reduction methods will be developed to analyze the complex spatiotemporal patterns of glomerular activity elicited by disease and healthy control samples. From this analysis, the key features of neural activity that underpin disease detection will be identified, and related to specific glomeruli. Glomeruli of interest will then be used to isolate the volatile organic compounds of relevance, through gas chromatography-olfactometry in parallel with gas-chromatography/mass-spectrometry. Additionally, quantitative methods will be developed for the alignment of neural spaces across multiple mice, using a minimal number of odors. This will render odor features translatable across animals, allowing for the decoding of disease in mice without extensive training data collection. The developed experimental and computational pipeline will be then applied to detect and decipher odorprints of multiple human diseases. Understanding how olfactory systems detect disease has the potential to revolutionize medical diagnostics, particularly with respect to early and noninvasive screening. But it will also constitute progress in ‘cracking the olfactory code’, with our understanding of olfaction currently lagging behind vision and audition. From an evolutionary perspective, the natural stimuli of olfaction were the metabolic states of food, mates, peers, and predators, rarely the monomolecular odorants commonly used in olfaction research today. While this project has an applied aim of medical diagnostics, the path to that aim proceeds via a deep understanding of some of the fundamental, yet still mysterious, principles of olfaction.", "keywords": [ "Afferent Neurons", "Algorithms", "Alzheimer&apos", "s Disease", "Animals", "Area", "Axon", "Behavioral", "Biological", "Biological Assay", "Blood", "Brain", "COVID-19", "Calcium", "Canis familiaris", "Chemicals", "Chronic", "Code", "Cognitive", "Communication", "Complex", "Computing Methodologies", "Data Collection", "Detection", "Development", "Diabetes Mellitus", "Diagnosis", "Diagnostic", "Dimensions", "Disease", "Disease model", "Environment", "Ethology", "Food", "Future", "Gas Chromatography", "Image", "Implant", "Implanted Electrodes", "In Vitro", "Infection", "Intercept", "Malaria", "Malignant Neoplasms", "Malignant neoplasm of lung", "Mass Fragmentography", "Mass Spectrum Analysis", "Metabolic", "Metabolic Diseases", "Methods", "Modernization", "Monitor", "Mus", "Neuropil", "Neurosciences", "Noise", "Nose", "Odors", "Olfactory Pathways", "Optics", "Parkinson Disease", "Partner in relationship", "Pattern", "Pattern Recognition", "Physiology", "Population", "Preparation", "Process", "Public Health", "Rattus", "Research", "Resolution", "Sampling", "Signal Transduction", "Smell Perception", "Stimulus", "Techniques", "Technology", "Training", "Translating", "Tuberculosis", "Urine", "Vision", "Volatilization", "analytical method", "awake", "clinical diagnostics", "combinatorial", "computational pipelines", "detection method", "detection platform", "diagnostic assay", "diagnostic strategy", "disease diagnostic", "experimental study", "human disease", "imaging modality", "improved", "in vivo", "innovation", "insight", "interest", "miniaturize", "mouse model", "neural", "neuromechanism", "noninvasive diagnosis", "novel", "olfactory bulb", "olfactory receptor", "olfactory sensory neurons", "pandemic disease", "peer", "preservation", "public health emergency", "rapid diagnosis", "receptor", "remote diagnosis", "response", "scale up", "screening", "sensor", "spatiotemporal", "volatile organic compound" ], "approved": true } }, { "type": "Grant", "id": "12103", "attributes": { "award_id": "1R01HD110422-01A1", "title": "The Impact of COVID-19 on Parent and Child Well-Being in Early Childhood", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 7137, "first_name": "LAYLA E", "last_name": "ESPOSITO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2027-06-30", "award_amount": 428914, "principal_investigator": { "id": 27966, "first_name": "Kierra Marie Pettit", "last_name": "Sattler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 989, "ror": "", "name": "UNIVERSITY OF NORTH CAROLINA GREENSBORO", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has changed nearly every aspect of life. Research is beginning to document the disproportionate impact of the pandemic on parents and children; however, much of the research does not assess the multi-dimensional nature of the pandemic, evaluate long-term outcomes, or measure multiple indices of well-being. In response to NOT-MH-21-330 (“Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations”), our team of experts in parenting, family well-being, risk and protective factors, and resilience, proposes to examine how parent and child well-being has been influenced by the pandemic. In addition, we propose to leverage and expand upon data from a prospective, longitudinal study (“Infant Growth and Development Study”, R01HD093662; R01HD110470 pending; PI: Leerkes) of 299 women and their infants, followed from pregnancy until children were 3.5 years old. We will recontact mothers when children are 4 years old and conduct a timeline follow-back interview with mothers and coparents about their COVID-related experiences to investigate how COVID has impacted parents’ and children’s well-being over time. Our three Specific Aims will examine: (1) how COVID-related experiences (both stressors and supports) impacted parent and child well-being across multiple dimensions during early childhood; (2) racial/ethnic and household income disparities in the impact of COVID-related stressors across multiple dimensions of well-being and potential protective factors (i.e., social support, supportive coparenting, neighborhood quality); and (3) how timing of COVID-related stressors and supports influences parent and child well-being. Parent outcomes will include social strain, positive parenting, economic strain, and physical and mental health. Child outcomes will include socioemotional adjustment, pre-academic skills, and health. Data will be assessed via parent report and interviewer observations. The proposal addresses critical knowledge gaps including: an exclusive focus on negative COVID experiences, a focus on single or narrow domains of parent and child well-being during the pandemic, and a lack of attention to heterogeneity in the impacts of the pandemic across families. Results will have important implications for understanding which parents and children need the most support in the current pandemic, as well as informing prevention and intervention programs aiming to promote parent and child well-being in future pandemics.", "keywords": [ "4 year old", "5 year old", "Academic skills", "Address", "Adverse effects", "Attention", "Back", "Behavioral", "Birth", "Buffers", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "Child", "Child Rearing", "Child Welfare", "Data", "Development", "Dimensions", "Distress", "Economics", "Ethnic Origin", "Family", "Family Relationship", "Future", "Growth and Development function", "Health", "Heterogeneity", "Hour", "Household", "Income", "Infant", "Influentials", "Interview", "Interviewer", "Investigation", "Knowledge", "Life", "Link", "Measures", "Mental Health", "Mothers", "National Institute of Child Health and Human Development", "Nature", "Neighborhoods", "Outcome", "Parents", "Personal Satisfaction", "Postpartum Period", "Poverty", "Pregnancy", "Prevention program", "Public Health", "Race", "Recontacts", "Reporting", "Research", "Resources", "Risk", "Risk Factors", "Schools", "Social Interaction", "Social support", "Special Supplemental Nutrition Program for Women Infants and Children", "Strategic Planning", "System", "Testing", "Time", "Underserved Population", "Vulnerable Populations", "Woman", "Work", "caregiving", "cohort", "coronavirus disease", "current pandemic", "early childhood", "economic disparity", "economic impact", "emotional adjustment", "experience", "family support", "future pandemic", "health disparity", "high school", "income disparities", "indexing", "infancy", "interest", "intervention program", "longitudinal prospective study", "maltreatment", "pandemic disease", "pandemic impact", "parental influence", "physical conditioning", "prenatal", "programs", "protective factors", "racial disparity", "resilience", "response", "satisfaction", "social", "stressor", "timeline" ], "approved": true } }, { "type": "Grant", "id": "12104", "attributes": { "award_id": "1R01AG080137-01A1", "title": "Mechanisms underlying COVID-19 induced Neurocognitive Dysfunction", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26177, "first_name": "Maja", "last_name": "Maric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2028-05-31", "award_amount": 639561, "principal_investigator": { "id": 27967, "first_name": "PAUL E", "last_name": "SCHULZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, which causes Coronavirus Disease 2019 (COVID-19), has become a global health crisis. To date, more than 6.5 million deaths from COVID-19 have been reported worldwide. Amongst survivors, neurocognitive dysfunction and neuropsychiatric disorders, such as anxiety and depression, are increasingly recognized and can persist for months, or even years. This enduring neurocognitive and neuropsychiatric distress obligates us to address critical questions about their duration, risk factors, and underlying mechanisms. The goal of this project is to test the hypothesis that SARS-CoV-2 promotes cognitive decline in subjects who were previously normal via stimulating inflammatory pathways, with the greatest risk being in older adults, females, and those from underrepresented groups. We propose to utilize patients in our biorepository, who were hospitalized with SARS-CoV-2 infection, to achieve three Specific Aims: (1) to determine the type and duration of neurocognitive dysfunction present; (2) to ascertain risk factors for ongoing cognitive decline, including sex, age, race/ethnicity and comorbidities; and, (3) to verify that persistent neuroinflammation underlies cognitive decline. To achieve these Aims, our team has established a well-curated, highly diverse biorepository of more than 650 patients hospitalized with COVID-19. About 15% have succumbed to COVID-related illnesses; however, 37% have continued to return for testing at 3-6 and 12-months post hospitalization. Preliminary data demonstrates that 30% of subjects returning at one year show progressive cognitive decline, which is associated with elevated markers of inflammation and neuronal stress. Here we propose to follow these patients and perform detailed cognitive testing and assess biomarkers from their blood- serum, spinal fluid, and imaging to explicate the type and time course of cognitive changes present, the risk factors associated with cognitive dysfunction, and whether inflammation-induced neuronal distress underlies progressive neurocognitive impairment. This proposal is innovative because we are evaluating the long-term neurocognitive consequences of severe COVID-19 from a cohort that we have followed since the onset of the pandemic, which has provided preliminary data supporting our Aims. Moreover, we have brought together investigators with expertise in cognitive assessment and treatment, and basic and translational research, all in the setting of a strong institutional infrastructure. Our work is significant because understanding the role of persistent neuroinflammation in COVID-19-induced cognitive dysfunction will greatly enhance our ability to rationally test immunosuppressants for this very debilitating disorder.", "keywords": [ "2019-nCoV", "Address", "Age", "Anatomy", "Anti-Inflammatory Agents", "Anxiety", "Attention", "Basic Science", "Biological Markers", "Blood", "COVID-19", "COVID-19 impact", "COVID-19 mortality", "Cerebrospinal Fluid", "Characteristics", "Cognitive", "Data", "Development", "Disease", "Distress", "Elderly", "Ethnic Origin", "Exhibits", "Female", "Functional disorder", "Goals", "Hospitalization", "Hospitals", "Image", "Immunoglobulin Therapy", "Immunosuppressive Agents", "Impaired cognition", "Infection", "Inflammation", "Inflammatory", "Infrastructure", "Institution", "Intervention", "Intravenous Immunoglobulins", "Lead", "Learning", "Link", "Medical", "Medical Records", "Memory", "Mental Depression", "Mood Disorders", "Neurocognitive", "Neurocognitive Deficit", "Neurologic", "Neurologic Symptoms", "Neurons", "Neuropsychological Tests", "Participant", "Pathway interactions", "Patients", "Peripheral", "Persons", "Plasma Exchange", "Positron-Emission Tomography", "Probability", "Quality of life", "Race", "Reporting", "Research Personnel", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Screening procedure", "Serum", "Stress", "Stroke", "Survivors", "Testing", "Thick", "Time", "Translational Research", "Underrepresented Populations", "Work", "biobank", "brain size", "cognitive change", "cognitive testing", "cohort", "comorbidity", "comparison control", "coronavirus disease", "digital", "executive function", "functional disability", "global health", "gray matter", "infection rate", "inflammatory marker", "innovation", "neuroinflammation", "neuropsychiatric disorder", "neuropsychiatry", "older patient", "pandemic disease", "participant enrollment", "post-COVID-19", "processing speed", "prospective", "screening", "severe COVID-19", "sex", "tau-1", "therapy design", "verbal" ], "approved": true } }, { "type": "Grant", "id": "12105", "attributes": { "award_id": "1R21AI175986-01", "title": "An L-Aptamer-Displacement Assay for High-Throughput Screening of RNA-Targeted Small Molecule Antivirals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6115, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2025-08-31", "award_amount": 167125, "principal_investigator": { "id": 27968, "first_name": "Jonathan Thomas", "last_name": "Sczepanski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1996, "ror": "", "name": "TEXAS A&M UNIVERSITY", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "While the vast majority of antiviral efforts to combat severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) focus on essential viral proteins, emerging evidence shows that conserved viral RNA (vRNA) structural elements are compelling targets with the potential for pan-antiviral activity. Despite this promise, however, selective targeting of RNA using drug-like small molecules remains challenging. In particular, methodologies for screening small molecule libraries against RNA remain underdeveloped, and do not adequately address the central problem of target specificity. As a result, RNA-targeted screens often fail to yield efficacious compounds. The proposed study takes direct aim at this technological gap through the development of a novel RNA-targeted screening technology using L-aptamers composed of mirror-image L-DNA. The PI previously established that L- aptamers can be evolved to bind native D-RNA structures, including SARS-CoV-2 vRNAs, with high affinity and selectivity. He now proposes to develop L-aptamers into RNA-specific competitive displacement probes for identifying small molecules with analogous properties. The general utility of nucleic acid aptamers, combined with the unique RNA-binding properties of L-aptamers, impart the proposed L-aptamer-displacement assay with several advantages over current RNA-centric screening technologies, and is hypothesized to facilitate the discovery of small molecules with unprecedented RNA-binding capabilities. The PI has already prepared an L-aptamer targeting a conserved RNA element with the SARS-CoV-2 genome, which will be developed into a biochemical assay that couples competitive displacement of the L- aptamer from the vRNA target with an optical readout (Aim 1). Using this assay, the PI will initiate a high- throughput screen to identify potent ligands targeting the corresponding vRNA. The most promising lead compounds will be evaluated for antiviral activity against SARS-CoV-2 infected cells (Aim 2). Parallel efforts will be undertaken to generate L-aptamers against additional SARS-CoV-2 RNA structures (Aim 3), which will be shuttled through this same pipeline. Successful completion of this project will signify a major advance in the area of RNA-targeted drug discovery. While combatting SARS-CoV-2 is the immediate goal, technologies developed herein are readily adaptable to target any RNA virus. By targeting essential RNA structures that are conserved across β-coronaviruses, the PI envision that this approach will allow for identification of antiviral compounds with broad-spectrum activity that might quickly pivot to address future outbreaks.", "keywords": [ "2019-nCoV", "Address", "Affinity", "Antibodies", "Antiviral Agents", "Area", "Attention", "Base Pairing", "Binding", "Biochemical", "Biological Assay", "COVID-19 pandemic", "Cells", "Charge", "Chemicals", "Couples", "DNA", "Development", "Drug Targeting", "Drug usage", "Elements", "Goals", "Image", "Ligands", "Methodology", "Molecular Conformation", "Nucleic Acids", "Nucleotides", "Oligonucleotides", "Optics", "Pharmaceutical Preparations", "Process", "Productivity", "Property", "Proteins", "Publishing", "RNA", "RNA Binding", "RNA Viruses", "RNA-targeting therapy", "Research Project Grants", "Ribose", "SARS-CoV-2 antiviral", "SARS-CoV-2 genome", "Specificity", "Structure", "Technology", "Time", "Untranslated RNA", "Vertebral column", "Viral", "Viral Genome", "Viral Physiology", "Viral Proteins", "Virus", "Virus Replication", "antiviral drug development", "aptamer", "betacoronavirus", "combat", "drug discovery", "enantiomer", "future outbreak", "high throughput screening", "novel", "screening", "small molecule", "small molecule inhibitor", "small molecule libraries", "stereochemistry", "variants of concern", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "12106", "attributes": { "award_id": "1DP1DA058978-01", "title": "Racial Equity in Systems to Treat Opioid Use Disorder for Everyone (RESTORE): A Pilot Randomized Controlled Trial", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21424, "first_name": "MINNJUAN WYNCEPHEL", "last_name": "Flournoy Floyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2028-07-31", "award_amount": 1053500, "principal_investigator": { "id": 27969, "first_name": "Sabrina Lynn", "last_name": "Smiley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 775, "ror": "https://ror.org/0264fdx42", "name": "San Diego State University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "I am a well-published, early stage medical sociologist applying for a NIDA-funded Racial Equity Visionary Award focused on the feasibility, acceptability, and preliminary efficacy of an innovative, mixed methods, community- engaged intervention targeting non-Hispanic Black (NHB) individuals with opioid use disorder (OUD). This study will apply my understanding of community needs and OUD, to test a novel intervention in a scalable setting, leveraging my role as a leader in this field to disseminate findings and improve treatment access nationwide. Opioid-related overdoses are increasing fastest in NHB individuals. In 2020, amid the COVID-19 pandemic, NHB overdose deaths increased by 45%, nearly double the increase in non-Hispanic Whites (NHW). Disproportionate increases in overdoses correspond to racial inequities in OUD treatment access and utilization. An effective treatment, buprenorphine, is concentrated among communities with high percentages of NHWs, higher income, and private insurance. Compared with NHW patients with OUD, NHB patients with OUD are 77% less likely to have an office visit that includes a buprenorphine prescription, despite similar prevalence of OUDs. This structural problem is at the foundation of my proposed research. Research focused on developing and testing culturally effective, community grounded, and structurally competent OUD treatments with rigorous implementation assessments is urgently needed to intervene on structural barriers to OUD treatment that operate in settings in which NHB individuals seek healthcare. Significant federal funding has expanded access to OUD treatment services in Community Health Centers (CHCs) that provide care to underserved populations and areas but barriers to accessing care remain in NHBs. I propose to prepare for a fully powered clinical trial by testing whether a buprenorphine treatment intervention protocol (Racial Equity in Systems to Treat Opioid Use Disorder for Everyone—RESTORE) that targets structural barriers to OUD treatment for NHB individuals is feasible in the context of CHCs. RESTORE draws upon concepts of structural competency, peer navigation, and culturally grounded OUD education for both patients and providers. Community engagement will be continuous, exemplified by the use of peer navigators to connect patients to care. RESTORE will be based in Southern California—an epicenter of the nation’s opioid crisis. Project Phases, guided by cutting edge implementation science, include 1) a qualitative investigation into provider and patient barriers to and facilitators of CHCs’ provision of buprenorphine specifically to NHB individuals with OUD; 2) the operationalization of RESTORE into routine care, using preliminary findings from Phase I; and 3) a pilot stepped-wedge randomized controlled trial to test the feasibility, acceptability, and preliminary efficacy of RESTORE, as well as the protocols, procedures and training in CHCs. This study has the potential to improve effective treatment rates in 4 clinics and provide an evidence-based intervention to be tested at scale across multiple states. Improvements in local treatments, designed to reach NHBs, will greatly reduce the current increase in overdose disparities.", "keywords": [ "Address", "Award", "Black American", "Black Populations", "Black race", "Buprenorphine", "COVID-19 pandemic", "California", "Caring", "Clinic", "Clinical Trials", "Communities", "Competence", "Disparity", "Education", "Evidence based intervention", "Foundations", "Funding", "Health Services Accessibility", "Healthcare", "Income", "Inequity", "Insurance", "Intervention", "Investigation", "Medical", "Methods", "National Institute of Drug Abuse", "Neighborhood Health Center", "Not Hispanic or Latino", "Office Visits", "Overdose", "Patients", "Phase", "Prevalence", "Privatization", "Procedures", "Protocols documentation", "Provider", "Publishing", "Racial Equity", "Randomized Controlled Trials", "Research", "Role", "System", "Testing", "Training", "Underserved Population", "Work", "black patient", "buprenorphine treatment", "community engagement", "design", "effective therapy", "feasibility testing", "implementation evaluation", "implementation science", "improved", "innovation", "novel", "opioid epidemic", "opioid mortality", "opioid overdose", "opioid use disorder", "overdose death", "patient-level barriers", "peer", "provider-level barriers", "racial disparity", "routine care", "sociologist", "treatment services", "underserved area" ], "approved": true } }, { "type": "Grant", "id": "12107", "attributes": { "award_id": "1UG3HL166785-01A1", "title": "1/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2024-08-31", "award_amount": 1445727, "principal_investigator": { "id": 27970, "first_name": "Jeremy R.", "last_name": "Beitler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27971, "first_name": "Daniel Stuart", "last_name": "Talmor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 771, "ror": "https://ror.org/04drvxt59", "name": "Beth Israel Deaconess Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Acute respiratory distress syndrome (ARDS) is a severe form of lung injury requiring hospitalization in intensive care and often invasive mechanical ventilation in effort to sustain life. ARDS can result from a variety of insults (e.g. pneumonia, sepsis, trauma, and pancreatitis), posing broad risk to the public health. With the COVID-19 pandemic, ARDS has become a leading cause of death in the US and globally. Yet, even pre-pandemic, ARDS occurred in 10% of US ICU admissions and had an associated mortality of 30-45%. Regardless of ARDS etiology, many survivors experience cognitive, psychological, and physical impairments persisting years after the acute illness resolves. Thus, there remains an urgent need to identify effective ARDS therapies. Invasive mechanical ventilation is potentially life-saving, but can worsen lung injury and patient outcomes if not precisely titrated to attenuate lung stress, which varies by patient with overdistension and atelectrauma (repetitive opening/closure of potentially recruitable lung). Alveolar edema and atelectasis reduce the functional aerated lung volume, such that tidal volume scaled to estimated healthy lung size (i.e. 6 mL/kg predicted body weight) may not always prevent overdistension. Similarly, positive end-expiratory pressure (PEEP) is routinely increased to recruit lung in patients with more severe hypoxemia, an approach that may exacerbate overdistension injury in patients most susceptible. An integrated strategy that mitigates the competing risks of atelectrauma and overdistension is needed. The range of lung stress observed in patients with ARDS receiving standard-of-care ventilation is often larger than that observed in healthy adults due to perturbed lung and chest wall mechanics, increasing risk of both atelectrauma and overdistension. In preclinical models and human cohort studies, lung injury and mortality are less when the ventilator is set to maintain lung stress in the healthy normal range. PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI) is a phase III multicenter randomized trial for adults with moderate-severe ARDS that tests whether precise ventilator titration to maintain lung stress within 0-12 cm H2O, the healthy normal range during relaxed breathing, will improve patient outcomes compared to guided usual care. In the precision ventilation arm, PEEP will be individualized to achieve lung stress of 0 cm H2O at end-expiration, and tidal volume individualized to achieve driving pressure of 12 cm H2O or the lowest possible. In the guided usual care arm, PEEP will be adjusted per usual care within limits set to avoid practice extremes; tidal volume of 6-8 mL/kg predicted body weight will be targeted unless plateau pressure exceeds 30 cm H2O, in which case tidal volume will be lowered. We will evaluate the effect of ventilator strategy on 60-day mortality (Aim 1), lung injury (Aim 2), and hemodynamic instability (Aim 3). Findings will help determine the role for individualizing ventilator support to reduce lung stress in ARDS and have potential to improve survival from this leading cause of death worldwide.", "keywords": [ "Acute", "Acute Respiratory Distress Syndrome", "Adipose tissue", "Admission activity", "Adult", "Alveolar", "Anatomy", "Atelectasis", "Attenuated", "Automobile Driving", "Blinded", "Body Weight", "Breathing", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "Cause of Death", "Chest wall structure", "Clinical", "Clinical Management", "Cognitive", "Cohort Studies", "Edema", "Esophagus", "Etiology", "Fibrosis", "Grant", "Healthcare Systems", "Heterogeneity", "Histologic", "Hospitalization", "Human", "Hypoxemia", "Impairment", "Injury", "Insufflation", "Intensive Care", "Intra-abdominal", "Life", "Lung", "Manometry", "Measures", "Mechanical Stress", "Mechanical ventilation", "Mechanics", "Modeling", "Morbidity - disease rate", "Multi-Institutional Clinical Trial", "National Heart Lung and Blood Institute", "Normal Range", "Outcome", "Pancreatitis", "Patient-Focused Outcomes", "Patients", "Periodicity", "Phase", "Pleural", "Pleural effusion disorder", "Pneumonia", "Positioning Attribute", "Positive-Pressure Respiration", "Pre-Clinical Model", "Predisposition", "Public Health", "Pulmonary Edema", "Randomized Controlled Trials", "Recovery", "Relaxation", "Research", "Risk", "Role", "Safety", "Sepsis", "Shapes", "Shock", "Stress", "Structure of parenchyma of lung", "Survivors", "Testing", "Tidal Volume", "Time", "Titrations", "Trauma", "Ventilator", "Ventilator-induced lung injury", "abdominal pressure", "arm", "atelectrauma", "circulating biomarkers", "cost", "experience", "expiration", "hemodynamics", "improved", "lung injury", "lung volume", "mortality", "novel", "personalized approach", "personalized strategies", "pre-clinical", "pre-pandemic", "pressure", "prevent", "psychologic", "randomized trial", "receptor for advanced glycation endproducts", "recruit", "soft tissue", "standard care", "standard of care", "stress reduction", "surfactant", "systemic inflammatory response", "treatment as usual", "usual care arm", "ventilation", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "12108", "attributes": { "award_id": "1R01HL166953-01A1", "title": "CMKLR1-Targeted Molecular Imaging of Inflammation as a Precision Medicine Tool in Acute Lung Injury and Fibrotic Lung Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26329, "first_name": "SIDDHARTH KAUP", "last_name": "Shenoy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2028-07-31", "award_amount": 646637, "principal_investigator": { "id": 27972, "first_name": "Sina", "last_name": "Tavakoli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Aberrant immune response to injury is a major pathogenic driver of adverse extracellular matrix remodeling after acute lung injury (ALI) and a wide range of fibrotic lung diseases (referred to inflammation-fibrosis axis). However, there is currently no established approach for noninvasive assessment of dysregulated lung inflammation. This gap along with the pathophysiological heterogeneity and variability of the clinical course of patients has hampered precision medicine management of fibrotic lung diseases. Chemokine-like receptor-1 (CMKLR1) is chemokine receptor which is overexpressed in profibrotic monocyte-derived macrophages, a leukocyte subset with crucial roles in the pathogenesis of lung fibrosis. Our central goal is to determine the potential of CMKLR1-targeted PET for i) quantitative imaging of lung inflammation; ii) prognostication of the risk of disease progression; and iii) early monitoring of the response to anti-inflammatory and anti- fibrotic interventions in experimental models of ALI and fibrotic lung injury. We will also address the clinical relevance of CMKLR1-targeted PET and its potential for future clinical translation by determining the expression of CMKLR1 in the lungs of patients with COVID-19 and several categories of fibrotic lung diseases vs. healthy controls. Our preliminary data revealed a significant increase in lung uptake of a novel CMKLR1-targeted tracer (64Cu-NODAGA-CG34) in two murine models of lipopolysaccharide-induced ALI and bleomycin-induced fibrotic lung injury, which was primarily driven by the accumulation of monocyte-derived macrophages. Our central hypothesis is that i) CMKLR1 serves as a biomarker of monocyte-derived macrophages in ALI and fibrotic lung diseases; hence its targeted imaging by 64Cu-NODAGA-CG34 PET allows for ii) predicting the risk of progression into sustained inflammation and fibrosis; and iii) monitoring the early therapeutic response to anti-inflammatory and anti-fibrotic interventions. We propose three Specific Aims: Specific Aim 1: To determine the immunoprofile of CMKLR1-expressing leukocytes in A) murine models of ALI and fibrotic injury, and B) lung specimens of patients with COVID-19 and fibrotic lung diseases. Specific Aim 2: To validate the accuracy of CMKLR1-targeted PET as a biomarker of inflammation at different stages of ALI and fibrotic injury in murine models. Specific Aim 3: To determine the potential of CMKLR1-targeted PET in A) disease prognostication; and B) early detection of the therapeutic response in murine models of ALI and fibrotic lung injury. Impact: By determining the role of CMKLR1-targeted PET for imaging macrophage-driven inflammation and defining the expression of CMKLR1 across various fibrotic lung diseases, this proposal may lead to a precision medicine strategy that allows for i) improved risk stratification; ii) prospective identification of patients with a high likelihood of favorable response to anti-inflammatory/anti-fibrotic interventions (hence, sparing the others from adverse effects and costs); & iii) personalized treatment adjustment based on early monitoring of the response.", "keywords": [ "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Address", "Adverse effects", "Anti-Inflammatory Agents", "Biological", "Biological Assay", "Biological Markers", "Bleomycin", "CMKLR1 gene", "COVID-19", "COVID-19 patient", "Categories", "Clinical", "Data", "Development", "Dexamethasone", "Diesel Exhaust", "Disease", "Disease Outcome", "Disease Progression", "Disease stratification", "Early Diagnosis", "Experimental Models", "Extracellular Matrix", "Fibrosis", "Flow Cytometry", "Future", "Goals", "Heterogeneity", "Histologic", "Histology", "Image", "Immune response", "Inflammation", "Inflammatory", "Injury", "Interstitial Lung Diseases", "Intervention", "Label", "Leukocytes", "Ligands", "Lipopolysaccharides", "Lung", "Lung diseases", "Mediating", "Molecular Target", "Monitor", "Occupational", "Organ", "Pathogenesis", "Pathogenicity", "Pathologic Processes", "Patients", "Pirfenidone", "Plasma", "Play", "Positron-Emission Tomography", "Process", "Pulmonary Fibrosis", "Pulmonary Inflammation", "Pulmonary function tests", "Role", "Sarcoidosis", "Severities", "Severity of illness", "Specimen", "Techniques", "Tissues", "Tracer", "Validation", "Viral Pneumonia", "X-Ray Computed Tomography", "chemokine receptor", "cigarette smoke-induced", "clinical translation", "clinically relevant", "cost", "diagnostic strategy", "disease prognosis", "disorder risk", "fibrotic interstitial lung disease", "fibrotic lung", "fibrotic lung disease", "improved", "inflammatory lung disease", "lung injury", "macrophage", "molecular imaging", "monocyte", "mortality risk", "mouse model", "novel", "novel marker", "overexpression", "particle", "patient stratification", "peptidomimetics", "personalized management", "personalized medicine", "precision medicine", "prognostication", "prospective", "quantitative imaging", "radiotracer", "recruit", "response", "response to injury", "risk prediction", "risk stratification", "spatiotemporal", "targeted imaging", "tool", "treatment response", "uptake" ], "approved": true } }, { "type": "Grant", "id": "12109", "attributes": { "award_id": "1RF1AG083090-01", "title": "Role of kynurenic acid in higher cognitive deficits: Mechanism and treatment strategies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12592, "first_name": "MOLLY V.", "last_name": "WAGSTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2026-08-31", "award_amount": 2168393, "principal_investigator": { "id": 27973, "first_name": "MIN", "last_name": "WANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed research will examine whether increased kynurenine inflammatory signaling with advancing age impairs higher cortical function through blockade of NMDAR and α7-nAChR, producing cognitive deficits that can be reversed by agents that inhibit kynurenine metabolism. Inflammation induces the conversion of tryptophan to kynurenine, a process that increases with age, and becomes especially prominent in Alzheimer’s Disease (AD), and with infection (e.g. from COVID19). Importantly, kynurenine is further metabolized to kynurenic acid (KYNA), which blocks NMDAR and likely α7-nAChR. Our research has shown that the working memory-related firing of “Delay cells” in primate dorsolateral prefrontal cortex (dlPFC) is heavily dependent on NMDAR neurotransmission with permissive α7-nAChR actions. As KYNA blocks both of these receptors, the increased production of KYNA in the aging brain may be particularly detrimental to dlPFC neuronal firing, and may contribute to the reduced dlPFC neuronal firing and working memory deficits observed in aged monkeys. The proposed research will perform the first examination of KYNA actions on primate dlPFC neuronal firing during working memory in young vs. aged rhesus monkeys, and will test for its interactions with NMDAR and α7-nAChR. We will also examine strategies to restore neuronal firing and working memory performance in aged monkeys by reducing KYNA production, coupled with enhanced cholinergic actions to optimize dlPFC neuronal physiology. These data may provide strategies to protect higher cortical circuits in cognitive disorders with high levels of KYNA production such as AD. Aim 1 will examine how local iontophoresis of exogenously applied KYNA (Aim 1A), or agents that alter the endogenous generation of KYNA (Aim 1B), influences Delay cell firing in young and aged monkeys. Preliminary data indicate that KYNA greatly reduces working memory- related neuronal firing, and that inhibition of KYNA synthesis can boost delay-related firing in aged monkey neurons. Aim 2 will test for KYNA actions at the glycine site on the NMDAR (Aim 2A), and at α7-nAChR (Aim 2B) in dlPFC, testing the hypothesis that KYNA blockade of these receptors markedly reduces Delay cell firing. Preliminary data are consistent with KYNA having both NMDAR and α7-nAChR blocking properties. Aim 3 will examine strategies to optimally restore dlPFC Delay cell firing (Aim 3A) and working memory performance (Aim 3B) in aged monkeys by combining agents that inhibit KYNA production with galantamine, a cholinesterase inhibitor and α7-nAChR positive allosteric modulator that is already approved for the treatment of AD. Given that dlPFC Delay cells require both NMDAR and α7-nAChR stimulation to sustain firing, we hypothesize that this combination may optimize dlPFC physiology and working memory performance in aged monkeys. The use of oral administration of compounds in Aim 3B may identify dosing regimens that can facilitate translation to human use, boosting higher cognitive abilities in patients with AD or other inflammatory disorders, e.g. “long-COVID”, associated with dlPFC cognitive deficits and high levels of kynurenine.", "keywords": [ "Acids", "Age", "Agonist", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease patient", "Alzheimer&apos", "s disease risk", "Animal Model", "Attention", "Behavioral", "Behavioral Assay", "Brain", "COVID-19", "COVID-19 pandemic", "Cells", "Cholinergic Receptors", "Cholinesterase Inhibitors", "Clinical", "Cognition Disorders", "Cognitive deficits", "Combined Modality Therapy", "Coupled", "Data", "Disease", "Dose", "Elderly", "Elderly woman", "Enzymes", "Family", "Galantamine", "Generations", "Glycine", "Impaired cognition", "Impairment", "Infection", "Inflammation", "Inflammatory", "Iontophoresis", "Kynurenic Acid", "Kynurenine", "Long COVID", "Macaca mulatta", "Memory impairment", "Metabolism", "Molecular", "Monkeys", "N-Methyl-D-Aspartate Receptors", "N-Methylaspartate", "Neurons", "Oral Administration", "Pathology", "Pathway interactions", "Patients", "Performance", "Physiological", "Physiology", "Plasma", "Prefrontal Cortex", "Primates", "Process", "Production", "Property", "Reducing Agents", "Regimen", "Regulation", "Research", "Rodent", "Role", "SARS-CoV-2 infection", "Sensory", "Sepsis", "Serine", "Short-Term Memory", "Signal Transduction", "Site", "Study models", "Synapses", "Testing", "Therapeutic", "Time", "Translating", "Tryptophan", "aged", "aging brain", "alpha-bungarotoxin receptor", "antagonist", "cholinergic", "clinically relevant", "cognitive ability", "cognitive performance", "executive function", "experimental study", "inhibitor", "insight", "neurotransmission", "oculomotor", "optimal treatments", "permissiveness", "pharmacologic", "positive allosteric modulator", "receptor", "response", "side effect", "tau Proteins", "translation to humans", "treatment strategy" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1405, "count": 14046 } } }